June 19, 2020News

Joining forces to discover new therapies!

The Quebec Breast Cancer Foundation (QBCF) and the Canadian Cancer Society (CCS), two leading organizations in funding breast cancer research, together with the biopharmaceutical research consortium CQDM, are proud to support the research conducted by Professor Yves St-Pierre at INRS-Institut Armand-Frappier. Valued at $1.15M, the project will support the development of next-generation immunotherapies against triple-negative breast cancer.

The targeted approach used by Professor St-Pierre and his team will allow the specific inhibition of galectins, a class of proteins with immunosuppressive properties that are overexpressed in tumor cells associated with several cancers, including triple negative breast cancer. This particularly aggressive form of the disease is also associated with a high risk of recurrence, especially in the first five years post-diagnosis.

“We are committed to supporting breast cancer patients across Quebec. We demonstrate this by collaborating with partners who make it possible to fund innovative research and make it accessible to improve patient survival. Professor St-Pierre’s project will meet the needs of breast cancer patients who have fewer treatment options,” said Karine Ippersiel, President and CEO of the Quebec Breast Cancer Foundation.

Professor Yves St-Pierre at INRS-Institut Armand-Frappier.

“The Canadian Cancer Society will invest a portion of the funds raised during the CIBC Run for the Cure in Professor Yves St-Pierre’s research,” said Denis Lalonde, Executive Vice-President, Quebec and French Canada. “Our actions today demonstrate how we can make it possible to advance the cause of cancer. The partnership between CCS, QBCF and CQDM allows us to support one of our leading researchers in immunotherapy. This project will also help many Quebec women dealing with hard-to-treat forms of breast cancer for which there are few effective treatments.”

“CQDM is pleased to collaborate with two leading figures in the fight against cancer to support the research led by Professor St-Pierre at INRS-Institut Armand-Frappier. We are also proud to direct our resources in support of a common cause: saving the lives of women dealing with breast cancer,” said Diane Gosselin, President and CEO of CQDM. “This type of collaboration truly reflects CQDM’s mission to accelerate the discovery of innovative drugs addressing unmet medical needs, such as triple negative breast cancer.

Professor St-Pierre’s research project will also receive funding from the Fondation Armand-Frappier, GlycoNet, Zymeworks and Pfizer. Click here to read the press release.

For information or interview requests, please contact:

Marie-Pier Cornellier
Quebec Breast Cancer Foundation
819 572-1254

Marine de Saint Lager
Canadian Cancer Society
514 238-4820

Diane Gosselin Ph. D., MBA, ASC
514 766-6661 (2191)

Make a donation Make a donation